Edesa Biotech increases ATM offering capacity to $2.26M; discloses prior sales of $3.72M

Edesa Biotech, Inc.

Prospectus supplement filed to increase max aggregate offering under ATM to $2,262,508.
Prior sales: $3.72M under Sept 2025 prospectus and $837K under Oct 2024 supplement.
Legal opinion of Fasken Martineau DuMoulin LLP regarding validity of shares attached.

item 8.01 item 9.01

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-007918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.